Key result
Extended use of direct oral anticoagulants beyond 12 months for pulmonary embolism requires careful balancing of the estimated risk of recurrent VTE against the non-negligible risk of bleeding.
Why the study?
Whether anticoagulant treatment reduces mortality after index pulmonary embolism remains to be defined, and the benefit of life-long anticoagulation is counterbalanced by bleeding risks.
Does extended anticoagulant treatment reduce recurrent VTE and mortality without excessive bleeding risk in patients with pulmonary embolism?
Design
Literature review
Authors
Loading...
May guide individualized DOAC duration decisions after PE; leaves open prospective validation of risk thresholds.
Does extended anticoagulant treatment reduce recurrent VTE and mortality without excessive bleeding risk in patients with pulmonary embolism?
Extended use of direct oral anticoagulants beyond 12 months for pulmonary embolism should be carefully weighed against the non-negligible risk of bleeding.
Becattini et al. (2020) conducted a review in Pulmonary embolism. Extended anticoagulant therapy (direct oral anticoagulants) vs. Discontinuation of anticoagulants was evaluated on Recurrent venous thromboembolism (VTE) and bleeding. Extended use of direct oral anticoagulants beyond 12 months for pulmonary embolism requires careful balancing of the estimated risk of recurrent VTE against the non-negligible risk of bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: